CiToxLAB increases capabilities in reprotoxicology and juvenile studies

Appoints Paul Barrow as director of scientific projects and client consulting

CiToxLAB, a French contract research organisation (CRO) involved in non-clinical research, has appointed Paul Barrow as director of scientific projects and client consulting.

Barrow has more than 30 years’ experience in preclinical safety testing, gained through working for the pharmaceutical industry and CROs in France, the UK and Italy.

Most recently Barrow was a director of toxicology at Ricerca Biosciences. In more than 10 years at Ricerca, he collaborated with more than 100 clients from the pharmaceutical, biotech, chemical and food industries to devise and execute non-clinical regulatory submission packages and to address pre- and post-marketing safety issues.

Barrow is a member of the Society of Toxicology, the Teratology Society, the European Teratology Society, Eurotox and is a European Registered Toxicologist.

You may also like

Research & Development

CiToxLAB expands inhalation test capabilities in North America and Europe

Opens rodent and non-rodent facility in Canada and will double rodent capacity in Hungary
Regulatory

CiToxLAB emerges from CIT and LAB Research merger

Will provide pre-clinical and specialist services from four facilities
Regulatory

CIT acquires assets of LAB Research Inc

This acquisition makes the new group one of the world’s top preclinical CROs
Research & Development

CIT to purchase LAB Research

Acquisition will take Canadian CRO out of receivership
Regulatory

MoonLake Immunotherapeutics faces Securities Class Action after disastrous Phase III trial results

The announcement about the trial results for the product candidate sonelokimab, a highly anticipated treatment for patients with skin disease, saw MoonLake investors' shares fall by about 90%, prompting an investigation into whether or not they were misled
Manufacturing

Samsung Bioepis and Phrontline join forces to advance best-in-class antibody-drug conjugate therapeutics for solid tumours

The pair will co-develop two investigational ADC assets directed against targets expressed in a broad range of cancers, adding a new class of bispecific and dual-payload ADC therapeutics to Samsung Bioepis' oncology portfolio
Research & Development

AlzeCure Pharma publishes response letter clarifying Alzstatin’s distinct mechanism in Alzheimer’s treatment

AlzeCure Pharma and leading academic collaborators have published a response in JPET addressing recent commentary on Alzstatin’s γ-secretase modulation data, reaffirming the promise of lead candidate ACD680 in Alzheimer’s therapy
Subscribe now